Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.75 |
| ▸ | CA9 | Q16790 | 1/20 | 0.75 |
| ▸ | TRIM24 | O15164 | 2/20 | 0.53 |
| ▸ | TRIM33 | Q9UPN9 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cyclopentanone SCHEMBL3628580 | 1.00 | CA1 (0.75) | CA1CA9TRIM24TRIM33ALDH1A1 | |
| SCHEMBL2562226 | 0.97 | CA1 (0.71) | CA1CA9TRIM24TRIM33ALDH1A1 | |
| Cyclohexanone SCHEMBL9561320 | 0.97 | CA1 (0.71) | CA1CA9TRIM24TRIM33ALDH1A1 | |
| SCHEMBL2348331 | 0.97 | CA1 (0.71) | CA1CA9TRIM24TRIM33ALDH1A1 | |
| SCHEMBL6201351 | 0.95 | CA1 (0.68) | CA1CA9TRIM24TRIM33ALDH1A1 | |
| SCHEMBL30742652 | 0.95 | CA1 (0.84) | CA1CA9TRIM24TRIM33ALDH1A1 | |
| Cyclohexanone SCHEMBL2324675 | 0.92 | CA1 (0.80) | CA1CA9TRIM24TRIM33ALDH1A1 | |
| SCHEMBL17515063 | 0.92 | CA1 (0.80) | CA1CA9TRIM24TRIM33ALDH1A1 | |
| SCHEMBL13317121 | 0.92 | CA1 (0.80) | CA1CA9TRIM24TRIM33ALDH1A1 | |
| SCHEMBL15141411 | 0.92 | CA1 (0.80) | CA1CA9TRIM24TRIM33ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7741456-B2 | Polyketides and antibiotics produced by combinatorial techniques | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2010-06-22 | — | — | US | disclosed |
| US-20080200659-A1 | Combinatorial polyketide libraries produced using a modular PKS gene cluster as scaffold | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2008-08-21 | — | — | US | disclosed |
| US-20060019371-A1 | Macrolide analogs | NATIONAL SCIENCE FOUNDATION | 2006-01-26 | — | — | US | disclosed |
| US-6984515-B2 | Generation of preferential nucleotide sequences coding enzymatic polypeptide; obtain cell, transform with vector coding enzymatic polypeptide, express vector, detect polypeptide | THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2006-01-10 | — | — | US | disclosed |
| US-6927057-B2 | Macrolide analogs | KOSAN BIOSCIENCES (US) | 2005-08-09 | — | — | US | disclosed |
| US-6558942-B1 | Compound for use in the generation of antibiotics | THE LELAND STANFORD JUNIOR UNIVERSITY | 2003-05-06 | — | — | US | disclosed |
| EP-0098367-A2 | Process for preparing macrocyclic ketol actones | HÜLS AKTIENGESELLSCHAFT (DE) | 1984-01-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080200659-A1 | Combinatorial polyketide libraries produced using a modular PKS gene cluster as scaffold | COASY, KARS1, EMG1 | CA1 4814/4885CA9 4363/4885TRIM24 916/4885 |
| US-20060019371-A1 | Macrolide analogs | COASY, LSS, EMG1 | CA1 4873/4885CA9 4531/4885TRIM24 1313/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.